Barclays Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Barclays from $32.00 to $11.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the company. JMP Securities reissued a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a report on Tuesday, April 29th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Monday, April 28th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, Scotiabank decreased their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $23.89.

Kura Oncology Stock Down 0.3 %

KURA stock opened at $6.47 on Friday. The company has a market cap of $522.63 million, a price-to-earnings ratio of -2.74 and a beta of 0.50. The company has a fifty day moving average price of $6.73 and a 200 day moving average price of $9.52. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. Sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently added to or reduced their stakes in KURA. Vanguard Group Inc. boosted its stake in Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock worth $41,973,000 after buying an additional 615,211 shares during the last quarter. RA Capital Management L.P. acquired a new stake in shares of Kura Oncology in the fourth quarter worth approximately $38,769,000. Millennium Management LLC grew its holdings in Kura Oncology by 180.1% in the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the period. Franklin Resources Inc. increased its position in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after purchasing an additional 23,113 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Kura Oncology by 35.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company’s stock worth $12,419,000 after purchasing an additional 372,196 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.